PTO/SB/08 (07/05)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Application Number Substitute for form 1449/PTO 10/714,078 Filing Date November 14, 2003 INFORMATION DISCLOSURE First Named Inventor Gunars Valkirs STATEMENT BY APPLICANT 1641 (Use as many sheets as necessary) Art Unit Examiner Name Lisa V. Cook 36671-743.503 1 Of 7 Attorney Docket Number Sheet

		U.S. P.	ATENT DOC	UMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patestee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/L.C./	1.	US 2002/0052000 A1	05/02/2002	Parthasarathy et al.	\/
	2.	US 2002/0106708 A1	08/08/2002	Thomas et al.	\ /
	3.	US 2003/0119064 A1	06/26/2003	Valkirs et al.	\/
	4.	US 2003/0199000 A1	10/23/2003	Valkirs et al.	
	5.	US 2003/0211544 A1	11/13/2003	Buechler et al.	
	6.	US 2003/0219734 A1	11/27/2003	Buechler	
	7.	US 2004/0121343 A1	06/24/2004	Buechler et al.	
$\neg$	8.	US 2004/0121350 A1	06/24/2004	Anderberg et al.	
	9.	US 2004/0126767 A1	07/01/2004	Anderberg et al.	
	10.	US 2004/0171064 A1	09/02/2004	Dahlen et al.	
	11.	US 2004/0176914 A1	09/09/2004	Buechler et al.	
	12.	US 2004/0203083 A1	10/14/2004	Buechler et al.	V
	13.	US 2004/0209307 A1	10/21/2004	Valkirs et al.	٨
	14.	US 2004/0253637 A1	12/16/2004	Buechler et al.	
	15.	US 2005/0148024 A1	07/07/2005	Buechler	
	16.	US 2005/0164317 A1	07/28/2005	Buechler et al.	
$\neg$	17.	US 2005/0255484 A1	11/17/2005	Valkirs et al.	
$\neg$	18.	US 2006/0051825 A1	03/09/2006	Buechler et al.	
$\neg$	19.	US 2006/0105419 A1	05/18/2006	Blankenberg et al.	
	20.	US 2007/0092911 A1	04/26/2007	Buechler et al.	
	21.	US 2007/0196880 A1	08/23/2007	Buechler et al.	<del>/</del>
	22.	US 2007/0218498 A1	09/20/2007	Buechler et al.	1
	23.	US 2007/0224643 A1	09/27/2007	Mcpherson et al.	/
/L.C./	24.	US 2007/0269836 A1	11/22/2007	Mcpherson	/

Examiner	Ilian Onald	Date	05/11/2000	
Signature	/Lisa Cook/	Considered	05/11/2009	
EXAMINER: I	sitial if reference considered, whether or not citation is in our	formance with MPEP 600. Deny line through a	itation if not in conformance and not considered. Include	

\*\*LAMMINIC: Smill reference considered, whether one ici classion is in conformance with MPIP 600. There like through classical it is on in conformance and on considered. Induke, copy of the conformance and one considered. Induke, copy of the conformance and one considered. Induke, copy of the conformance are view upon the view

The collector of information in regional by 27 (VT 1) 20 and 27 (The information in required to obtain or reads a benefit by the public which is to file (and by the USFTO in process) in This collector of information in regional by 17 (VT 1) 20 and 27 (The Information is required to obtain or reads a benefit by the public which is to file (and by the USFTO in process) in The collector is demanded to the first both the public which is public to the USFTO in process; and submitting the completed application form to the USFTO Time will very depending upon the individual contribution of the USFTO Time will very depending upon the individual contribution of the USFTO Time will very depending upon the individual contribution of the USFTO Time will very depending upon the individual contribution of the USFTO Time will very depending upon the individual contribution of the USFTO Time will very depending upon the individual contribution of the USFTO Time will very depending upon the individual contribution of the USFTO Time will very depending upon the individual contribution of the USFTO Time will very depending upon very dependent upon the USFTO Time will very depending upon the USFTO Time will very depending upon very dependent upon the USFTO Time will very depending upon very dependent upon the USFTO Time will very depending upon very dependent upon the USFTO Time will very dependent upon the USFTO Time very dependent upon the USFTO Time very dependent upon the USFTO

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known	
Substitute fe	or form 1449	PTO		Application Number	10/714,078
INFORM	IATION	DISC	LOSURE	Filing Date	November 14, 2003
STATEMENT BY APPLICANT				First Named Inventor	Gunars Valkirs
(Use as	many sheet	s as ne	cessary)	Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	2	Of	7	Attorney Docket Number	36671-743.503

		U.S. P.	ATENT DOC	UMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/L.C./	25.	US 2008/0045444 A1	02/21/2008	Whittaker	1
	26.	US 2008/0118924 A1	05/22/2008	Buechler	\
	27.	US 4,900,662	02/13/1990	Shah et al.	\ /
	28.	US 5,202,234	04/13/1993	Shah et al.	
	29.	US 5,382,515	01/17/1995	Shah et al.	
	30.	US 5,382,522	01/17/1995	Shah et al.	
$\neg$	31.	US 5,482,935	01/09/1996	Adelman et al.	
	32.	US 5,683,885	11/04/1997	Kieback	
	33.	US 5,795,725	08/18/1998	Buechler et al.	7
	34.	US 5,814,462	09/29/1998	Weinberger	1/
	35.	US 5,843,690	12/01/1998	Gargan	V
	36.	US 6,156,521	12/05/2000	Buechler et al.	Λ
	37.	US 6,174,686 B1	01/16/2001	Buechler et al.	
	38.	US 6,495,519 B1	12/17/2002	He et al.	
	39.	US 6,579,687 B1	06/17/2003	Buechler et al.	
	40.	US 6,627,404 B1	09/30/2003	Buechler et al.	
1	41.	US 6,939,678 B1	09/06/2005	Buechler et al.	
	42.	US 6,991,907 B1	01/31/2006	Buechler et al.	
_	43.	US 7,341,838 B2	03/11/2008	Buechler et al.	
	44.	US 7,358,055 B2	04/15/2008	Valkirs et al.	/
	45.	US 7,361,473 B2	04/22/2008	Valkirs et al.	/
/L.Č./	46.	US 7,427,490 B2	08/20/2002	Valkirs	/

Examiner Signature	/Lisa Cook/	Date 05/11/2009 Considered	

Signature:

FixAMPIRE: Usual if reference considered, whether or not classion is in conformance with MPIP 09. Draw line through classion if not in conformance and not considered. Include copy of this from with next communication in opticate. Applicant's insign centurine designation number (optional). See Janks Oxfor of USPTO Pacta Dousseries as were usuage, nor of MPIP 101. A "inter Official in this usual cité adoutment, but to new-later code (INPO Standard ST 3). The primate parties dominant in the include of the region of the Engenom approach the sensit insignation of the great residence in the region of the Engenom approach the sensition and the option of the Engenome approach the sensition after the great region of the Engenome approach in an adoption of the Standard ST 3 (1) of Agreement by the region of the Engenome and the Option of the Engenome and the Properties of the Engenome and the Courses under WPO Standard ST 3 (1) of Agreement by the sensition of the Standard ST 3 (1) of Agreement and the Standard ST 3 (1) of Agreement and the Standard ST 3 (1) of Agreement and Agreement and

does most tone in paging throughout promotion at authorit.

The collection of information in regarded to 77 (X 17) and 17 (X 17) and 18 (X 10) information in required to obtain or retain a branch ty the pating which is to 16; and the particular promotion in regarded to 18 (X 10) and 18 (X 10) an

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unlies it contains a valid form form formation.

				Con	nplete if Known
Substitute fo	or form 1449	/PTO		Application Number	10/714,078
INFORM	IATION I	DISC	LOSURE	Filing Date	November 14, 2003
STATEM	STATEMENT BY APPLICANT (Use as many sheets as necessary)			First Named Inventor	Gunars Valkirs
(Use as				Art Unit	1641
		Examiner Name	Lisa V. Cook		
Sheet	3	Of	7	Attorney Docket Number	36671-743.503

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	No.1	Foreign Patent Document Country Code <sup>3</sup> – Number <sup>6</sup> – Kind Code <sup>3</sup> (If Insum)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	To				
/L.C./	47.	WO 1998/043630 A1	08/10/1998	Ridker et al.		/				
	48.	WO 2001/042793 A2	06/14/2001	Hochstrasser et al.						
	49.	WO 2004/058055 A2	07/15/2004	Anderberg et al.	$\overline{}$					
	50.	WO 2004/094459 A2	11/04/2004	Buechler						
/L.C./	51.	WO 2004/094460 A2	11/04/2004	Buechler et al.						

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catolog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
/L.C./ 52.		ANDERSON, L. Candidate-Based Proteomics in the Search for Biomarkers of Cardiovascular Disease. J. Physiol. 563.1; 2004: 23-60.					
	53.	BARBER, et al. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 2004 Jun;35(6):1421-5. Epub 2004 Apr 8.					
	54.	BIDZSERANOVA, et al. Structure-activity studies on the effects of atrial natriuretic peptide, brain natriuretic peptide and their analogs on fear-motivated learning behavior in rats. Neuropeptides. 1992;23(2): 61-65.					
	55.	BREYER, J. dissenting. Supreme Court of The United States, No. 04-607. Laboratory Coproration of America Holdings, DBA Laborat, Petitioner v. Metabolite Laboratories, Inc., et al. June 22, 2006 (slip opinion) pages 1-15.					
	56.	CARVILLE, et al. Thrombus precursor protein (TpPTM): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin. Chem. 1996;42:1537-1541.					
/L.C.	57.	CHANG, et al. C-Reactive Protein Binds to Both Oxidized LDL and Apototic Cells Through Recognition of a Common Ligand: Phosphorylcholine of Oxidized Phospholipids.					

Examiner	1 0	Date	05/44/0000
Clauston	l /Lisa Cook/		05/11/2009
Signature		Considered	
*FYAMINER: I	mittal if reference considered, whether or not citation is in conformance with MPND 600.	Denny San through a	sitution if not in conformance and not considered. Include con-

\*EXAMINER: third if freference considered, whether or not critative is in conformance with NMER 00. Due has being decident for it in conformance and not considered. Include or profit for more than 1 conformance and not considered. Include or MIPP 901.04. "Enter Office that issued the document, by the ro-being conformation conformation and the conformation of the profit occurrent. "Ageleanth" using conformation of the profit occurrent. "Keel of occurrent by the pro-being conformation of the profit occurrent. "Keel of occurrent by the properties profit on instances of one document out PMID Standard 20.1 (In Frenchts." Agelleanth inspace; if remaintain is standard on the contract of the profit occurrent. "Keel of occurrent by the appears are used to the conformation of the profit occurrent." Keel of occurrent by the appears are profit on the conformation in standard on the contract of the contract of the profit occurrent. In the conformation of the profit occurrent in the profit of the conformation is unabled on the conformation of the profit occurrent occurrent of the profit occurrent oc

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known				
Substitute fo	r form 1449	PTO		Application Number	10/714,078			
INFORM	ATION	DISCI	OSURE	Filing Date	November 14, 2003			
STATEMENT BY APPLICANT				First Named Inventor	Gunars Valkirs			
(Use as	many sheet	s as nec	essary)	Art Unit	1641			
				Examiner Name	Lisa V. Cook			
Sheet	4	Of	7	Attorney Docket Number	36671-743.503			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numb (no.)		
	58.	CHOUDHRI, et al. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med. 1999 Jul 5;190(1):91-9.	
	59.	CHRISTENSON, et al. Standardization of cardiac troponin I assays: round Robin of ten candidate reference materials. Clin Chem. 2001 Mar;47(3):431-7.	
	60.	CLARK, et al. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997 Nov 28;238(1-2):53-6.	
	61.	COEROLI, et al. Nitric oxide production and perivascular tyrosine nitration following focal ischemia in neonatal rat. J Neurochem. 1998 Jun;70(6):2516-25.	
	62.	COSSINS, et al. Enhanced Expression of MMP-7 and MMP-9 in Demyelinating Multiple Sclerosis Lesions. Acta. Neuropathol. 1997;94:590-598.	
	63.	DE MEESTER, et al. In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine). Biochem Pharmacol. 1997 Jul 1;54(1):173-9.	
	64.	EIKELBOOM, et al. C-reactive protein in ischemic stroke and its etiologic subtypes. J Stroke Cerebrovasc Dis. 2003 Mar-Apr;12(2):74-81.	
	65.	FASSBENDER, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1944 Apr;122(2):135-9.	
	66.	FUKUI, et al. Focal Brain Edema and Natriuretic Peptides in Patients with Subarachnoid Hemorrhage. J. of Clin. Neuroscience. 2004;11(5): 507-511.	
/L.C./	67.	HARRINGTON, J.R. The Role of MCP-1 in Atherosclerosis. Stem Cells. 2000;18: 65-66.	

Examiner Signature	/Lisa Cook/	Date Considered	05/11/2009	

Explanations with next considered, whether or not classion is in conformance with MPTP 609. Draw like through classics if not in conformance and not considered. Include copy of this from with next consummission to applicate. Applicant is unique classics designation number (spitossis). See Radia Cooks of USFIO Draw Resources and away supera gove on MPTP of the Cooks of USFIO Draw Resources and away supera gove on MPTP of the Radia Cooks of USFIO Draw Resources and away supera gove on MPTP of the Radia Cooks of USFIO Draw Resources and away supera gove on MPTP of the Radia Cooks of USFIO Draw Resources and the Cooks of USFIO Draw Reso

clocks must here of English language Translation a stateful of the Table State of the Control of

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

ection of information unless it contains a valid OMB control number

				Complete if Known		
Substitute fo	or form 1449	PTO		Application Number	10/714,078	
INFORM	IATION:	DISCI	OSURE	Filing Date	November 14, 2003	
STATEM				First Named Inventor	Gunars Valkirs	
(Use as many sheets as necessary)				Art Unit	1641	
				Examiner Name	Lisa V. Cook	
Sheet	5	Of	7	Attorney Docket Number	36671-743.503	

Include name of the author (in CAPITAL LEITERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, eity and/or country where published.  HATFIELD, et al. CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model. Brain Res. 1992 Apr 17:57(2):249-52 (abstract only)  HEESCHEN, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. The Lancet. 2000;354: 261-272.  International Search Report and the Written Opinion of the International Searching Authority dated 07/03/2008 from PCT Application No. US05/38225.  International Search Report dated 10/20/2004 for PCT Application No. US04/26984.
a rat stroke model. Brain Res. 1992 Apr 17;577(2):249-52. (abstract only)  HEESCHEN, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. The Lancet. 2000;354: 261-272.  International Search Report and the Written Opinion of the International Searching Authority dated 07/03/2008 from PCT Application No. US05/38225.
syndromes in relation to therapeutic efficacy of tirofiban. The Lancet. 2000;354: 261-272.  International Search Report and the Written Opinion of the International Searching Authority dated 07/03/2008 from PCT Application No. US05/38225.
dated 07/03/2008 from PCT Application No. US05/38225.
International Search Report dated 10/20/2004 for PCT Application No. US04/26984.
KANEKO, et at., Circulating levels of $\beta$ -chemokines in systemic lupus erythematosus. J. Rheumatol. 26:568-573, 1999.
KLINE, et al. New diagnostic tests for pulmonary embolism. Ann Emerg Med. 2000 Feb;35(2):168-80.
LESCUYER, et al. Identification of Post-Mortem Cereberal Spinal Fluid Proteins as Potential Biomarkers of Ischemia and Neurodegeneration. Proteomics. 2004;(4): 2234-2241.
LINDON, J. C. Biomarkers: Present concepts and future promise. Preclinica. 2003;1: 221.
LIP, et al. Von Willebrand Factor and Its Relevance to Cardiovascular Disorders. Br Heart J. 1995;74:580-583.
MA, et al. RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats. Brain Res. 2003 Mar 21;966(2):167-74.
Management of the patient with stroke. Chapter One - Trends in stroke prevention and management. Available at: http://69.3.158.146/nurse/courses/nurseweek/NW0200/c1/p01.htm

05/11/2009 Signature Considered 

Date

coccs mark over it arguest anguage: remainted a statement of the control of the c

Examiner

/Lisa Cook/

## Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known	
Substitute fe	or form 144	9/PTO		Application Number	10/714,078
INFORM	IATION	DISC	LOSURE	Filing Date	November 14, 2003
STATEM	ENT BY	APP	LICANT	First Named Inventor	Gunars Valkirs
(Use as many sheets as necessary)				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	Sheet 6 Of 7		Attorney Docket Number	36671-743.503	

		NON PATENT LITERATURE DOCUMENTS
Examin Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
/L.C./	79.	McGIRT, et al. Serum Von Willebrand Factor, Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor Levels Predict the Onset of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrage. Neurosurgery. 2002;51(5):1128-1135.
	80.	Office Action from Japanese Patent Office dated 06/10/2008 for Japanese Application No. JP2003-521366 (in Japanese with English translation).
	81.	ORBE, et al. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. Journal of Thrombosis and Haemostasis 2007;5 (1), 91–97.
	82.	RUS, et al. Interleukin-6 and Interleukin-8 protein and Gene Expression in Human Arterial Atheroslcerotic Wall. Atheroslcerosis. 1996;127:263-271.
***************************************	83.	SHIRASAKI, et al. Serum S-100b protein as a biomarker for the assessment of neuroprotectants. Brain Res. 2004 Sep 24;1021(2):159-66.
	84.	STANEK, et al. Prognostic Evaluation of Neurohumoral Plasma Levels Before and During Beta Blocker Therapy in Advanced Left Ventricular Dysfunction. JACC. 2002;38(2): 436-442.
	85.	TAKEBAYASHI, et al. Association between circulating monocyte chemoattractant protein-1 and urnary albumin excretion in nonobese Type 2 diabetic patients. J Diabetes Complications. 2006 Mar-Apr;20(2):98-104.
	86.	TOMIDA, et al. Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. Stroke. 1998 Aug;29(8):1584-7.
	87.	UCHIYAMA et al., Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke, Semin. Thromb. Hemost. 23: 535-541 (1997).
/L.C./	88.	VASAN, et al. Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hyperthrophy and Systolic Dysfunction. JAMA. 2002;288(10): 1252-1259.

Examiner	/Lisa Cook/	Date	05/11/2009	
Signature		Considered	05/11/2009	

Signature:

\*\*EXAMMER: This ill reference considered, whether or not citation is in conformance with MPP 600. There flood through claimful in on in conformance and not considered. Include coay of this flow with next communication in applicant. \*\*Applicant\*\* in single citation designation number (optional). The reliant Coals of USP/TO Pater Decurrent as new unjour, or MPP 100.

\*\*Insert Office that less off in the Coarts, IN for the violent red (WPP) Coarts and the coarts of the princip of the Empirer must proceed the serial number of this pater discourse. \*\*Xind of decurrent by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 of Epocalité. \*\*Applicant is to place a deck mark here it English beingapt Transitions\*\* are standed.

PTO/SB/08 (07/05)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute fo	or form 144!	9/РТО		Application Number	10/714,078	
INFORM	ATION	DISC	LOSURE	Filing Date	November 14, 2003	
STATEM				First Named Inventor	Gunars Valkirs	
(Use as	many sheet	s as nec	essary)	Art Unit	1641	
				Examiner Name	Lisa V. Cook	
Sheet	7	Of	7	Attorney Docket Number	36671-743.503	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/L.C./	89.	VASAN, R. S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006 May 16;113(19):2335-62.			
	90.	ZHOU, et al. HBO suppresses Nogo-A, Ng-R, or RhoA expression in the cerebral cortex after global ischemia. Biochem Biophys Res Commun. 2003 Sep 19;309(2):368-76.			
/L.C./	91.	ZWEIG, et al. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561-77.			

Signature Considered	Examiner Signature	/Lisa Cook/	Date Considered	05/11/2009
----------------------	-----------------------	-------------	--------------------	------------

\*EXAMINE: this if reference contineed, whether are actions in conformation with MPE 60. Due the frough claims in 40 min conformation and opportunities and opportunities are conformation and opportunities and opportunities are conformation and opportunities are

clock risk her fi Taglish Inapage Trainfation is statisfied.

This collication of information is required by CTC 11 97 and 1 98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFIO to process) an opinionistic Confidentially is generated by 20 USE 1 22 and 7 USE 1 14. This collection is unlimited to that 2 hours to complete, including gathering, preparing, and assistanting the restriction of the Confidential or the Confidential Order or the Confidential Orde